Acadia Pharmaceuticals | ACAD - PE Price to Earnings


Acadia Pharmaceuticals reported 10.08 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
Acadia Pharmaceuticals 10.08 1.53 Mar/2026
ALKERMES 39.33 19.8 Mar/2026
Alnylam Pharmaceuticals 80.04 90.66 Mar/2026
Biogen 13.7 0.32 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Cara Therapeutics 27.77 117.09 Sep/2021
Corcept Therapeutics 113.58 71.67 Mar/2026
Eisai 35.61 8.98 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Incyte 15.35 0.51 Mar/2026
J&J 24.53 0.91 Mar/2026
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 28.09 807.38 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Prothena 22.11 11.37 Mar/2022
PTC Therapeutics 9.98 3.25 Dec/2025
Sarepta Therapeutics 27.27 0 Dec/2025
Vanda Pharmaceuticals 16.79 7.07 Jun/2023
Vertex Pharmaceuticals 25.82 0.33 Mar/2026